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c o r r e s p o n d e n c e
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Bevacizumab for Retinopathy of Prematurity
To the Editor: The study by Mintz-Hittner et al. 
(Feb. 17 issue)1 advances our knowledge about the 
use of bevacizumab for the treatment of retinop-
athy of prematurity, but important questions re-
main about this drug’s safety and efficacy. In the 
absence of functional vision testing or patient 
safety data, the sweeping endorsement of an ex-
perimental new treatment is unwarranted. Lack of 
protection against investigator bias is a concern. 
Assessment of the primary outcome (i.e., recur-
rence of retinopathy of prematurity requiring re-
treatment) by two ophthalmologists who were 
aware of the treatment assignments leaves the 
door open for such bias to influence results. These 
results were “validated” after retreatment by inde-
pendent photographic assessments, also without 
masking of the treatment received. Although 
Reynolds, in his editorial, states that the indepen-
dent reading center was similar to those in prior 
major studies of retinopathy of prematurity,2 this 
is not true. In the Cryotherapy for Retinopathy of 
Prematurity study (CRYO-ROP; ClinicalTrials.gov 
number, NCT00000133)3 and the Early Treatment 
for Retinopathy of Prematurity study (ETROP, 
NCT00027222),4 investigators assessing events rel-
evant to the primary outcome were not aware of 
the treatment assignments. Studies of the dose of 
bevacizumab, the timing of treatment, vision out-
come, and especially safety data are warranted.
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To the Editor: In response to the article by 
Mintz-Hittner et al.: we note that bevacizumab 
(an anti–vascular endothelial growth factor [VEGF] 
agent) is already being used as first-line or rescue 
treatment for retinopathy of prematurity in many 
middle and emerging economies. In these set-
tings, the population of babies with severe dis-
ease is very different from that in industrialized 
countries because more mature babies (gesta-
tional age of >31 wk) are also often affected.1 
This phenomenon has been termed the “third 
epidemic” of retinopathy of prematurity.2 Angio-
genesis is still active in many organs of these 
babies at the time of treatment of retinopathy of 
prematurity, yet the potential risks of anti-VEGF 
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agents may not be fully explained to parents, and 
access to medical legal redress is limited. It is 
imperative that the pharmacodynamics and safe-
ty profile of bevacizumab (or alternative agents) 
in the premature infant with acute retinopathy of 
prematurity and breakdown of the blood–ocular 
barrier be better delineated.3 Randomized clini-
cal trials that are adequately powered to detect 
adverse events and that have sufficiently long 
follow-up to assess neurodevelopmental outcomes 
are urgently needed. Until that time we would 
advocate that anti-VEGF medications be used 
only when laser photocoagulation fails and when 
informed consent is rigorously obtained.
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To the Editor: The Bevacizumab Eliminates the 
Angiogenic Threat of Retinopathy of Prematurity 
study (BEAT-ROP, NCT00622726) suggests that 
the intraocular injection of bevacizumab is use-
ful in the treatment of severe retinopathy of pre-
maturity, but unknown systemic and ocular safety 
issues remain a concern. To establish mortality 
risk, the authors suggest that a study with 2800 
infants is needed; since such a study would clear-
ly be difficult to conduct, systemic safety data 
will not be immediately available. The issue of 
systemic safety is still being debated in large tri-
als of anti-VEGF agents for other, more common 
neovascular eye diseases.1 Although the investi-
gators in the BEAT-ROP study administered half 
the dose of bevacizumab that is typically deliv-
ered, intravitreally, to adults, the premature in-
fant’s body weight is many times lower than an 
adult’s, and any systemic exposure is dispropor-
tionately greater. Systemic VEGF levels are almost 
fully suppressed 1 month after a single intraocu-
lar bevacizumab injection.2 VEGF contributes to 
lung development,3 and it is worrying that in the 
BEAT-ROP study, mortality with bevacizumab was 
higher than with laser treatment (6.6% vs. 2.6%), 
with four of the five deaths among those treated 
with bevacizumab resulting from low oxygen or 
respiratory failure. Finally, with respect to ocular 
safety, VEGF is needed for retinal differentiation 
and neuronal survival,4 and the safety effects of 
bevacizumab are therefore better ref lected in 
long-term visual and functional outcomes than 
in immediate structural complications.
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To the Editor: We are concerned about the 
strong recommendation made by Reynolds in his 
editorial regarding the BEAT-ROP study that in-
travitreal bevacizumab should replace conven-
tional laser therapy for the treatment of severe 
retinopathy of prematurity. Bevacizumab has been 
found in the systemic circulation long after intra-
vitreal injection.1 The historical lesson on anti-
angiogenesis drugs in infants was provided by 
the use of interferon alfa in the treatment of cap-
illary hemangiomas — spastic diplegia or other 
neuromotor abnormalities developed in almost 
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10% of the infants so treated.2 If the rate of neuro-
motor disturbance in infants of less than 26 weeks 
of age is approximately 16 to 28%,3 the BEAT-ROP 
study was too small to detect even a 10% increase 
in incidence of neurologic damage from beva ciz-
umab. Without larger studies that yield robust 
data on adverse outcomes, the recommendation 
that bevacizumab should be the treatment of 
choice would appear to be premature.
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The author replies: As Gilbert et al. note, intra-
vitreal bevacizumab injections are already being 
used to treat retinopathy of prematurity in many 
developing countries, and additional studies of 
the pharmacokinetics and safety of intravitreal 
bevacizumab and the systemic administration of 
bevacizumab are needed. In industrialized na-
tions, infants with retinopathy of prematurity 
have poor outcomes, probably because ever small-
er infants survive premature birth, and therefore 
the number of infants with zone I retinopathy of 
prematurity is increasing.
The data my colleagues and I reported, col-
lected at 6 months after treatment, suggest that 
intravitreal bevacizumab injections are more ef-
fective than laser treatment for zone I retinopa-
thy of prematurity. We did not suggest that this 
treatment should be considered the standard of 
care; however, we did state that additional stud-
ies should be designed to evaluate the long-term 
efficacy and safety of intravitreal bevacizumab 
injections to treat zone I disease and zone II dis-
ease and acknowledged the need to determine an 
appropriate follow-up schedule when using such 
therapy. We suggested that the evaluation of 
lower doses would be appropriate.
Regarding ocular efficacy, we cited the only 
study of human ocular pathology subsequent to 
intravitreal bevacizumab injection available to us 
when our article went to press.1 The results of 
this study indicated no ocular toxicity. However, 
we did not mention two rat studies of anti-VEGF 
therapy in which a neutralizing antibody to VEGF2 
and an inhibitor of VEGF receptor 2 tyrosine 
kinase3 were injected intravitreally. Both studies 
showed that anti-VEGF therapy reduced endothe-
lial-cell migration into the vitreous without inter-
fering with endothelial-cell migration into the 
retina toward a VEGF gradient. The results of 
these studies in animals are consistent with the 
results of our study. They also suggest that the 
loss of visual field may possibly be reduced by 
treatment with an anti-VEGF agent.
We realized during the planning stages that a 
lack of masking would be an issue, as it was in 
previous multicenter trials of approaches to treat 
retinopathy of prematurity (the CRYO-ROP and 
the ETROP studies) that yielded preliminary re-
sults (collected at 6 to 9 months after treatment). 
However, RetCam imaging, which provided ob-
jective documentation throughout the study, was 
a critical part of our study design. This imaging 
allowed multiple opinions of disease classifica-
tion and treatment responses. We intend to fol-
low these infants for 5 years (or longer) and to 
include assessments of neurodevelopmental out-
comes, as well as ocular outcomes, by indepen-
dent, masked examiners.
The decision to submit the article was fueled 
by concerns of the physicians who participated 
in this study. We thought that it would be un-
ethical to withhold the data from other physi-
cians who are responsible for the care of patients 
who present with severe zone I stage 3+ retinop-
athy of prematurity.
Helen A. Mintz-Hittner, M.D.
University of Texas Health Science Center at Houston  
 Medical School 
Houston, TX
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The editorialist replies: In my editorial, I noted 
many areas of concern about the BEAT-ROP study 
carried out by Mintz-Hittner and colleagues and en-
dorsed the use of bevacizumab to treat retinopathy 
of prematurity in a limited fashion. I agree that, 
according to the study design, the investigators 
were not masked. The study was, however, a pro-
spective, controlled, randomized, multicenter trial 
with an independent data and safety monitoring 
board and an independent reading center — all 
features of previous rigorously conducted trials 
designed to test approaches to the treatment of 
retinopathy of prematurity. As such, the BEAT-ROP 
study was superior to previous studies of case series 
of infants with retinopathy of prematurity treated 
with bevacizumab.1 In the CRYO-ROP study, pa-
tients whose eyes showed an anatomically defined 
level of serious disease (i.e., threshold retinopathy 
of prematurity) underwent peripheral cryosurgical 
retinal ablation. Only 7.6% of these treatable eyes 
had disease in zone I, but those eyes had a very 
high unfavorable anatomic result. The CRYO-ROP 
study did not initially provide visual results. The 
ETROP study reported in 2003, which mainly used 
laser therapy in place of cryosurgery, showed more 
favorable results for zone I serious retinopathy of 
prematurity, but some of that improvement may 
have been due to methodologic differences in the 
ways in which zone I retinopathy of prematurity 
was defined in the two studies. The study by Mintz-
Hittner et al. provided compelling evidence of a 
more efficacious intervention to treat zone I disease, 
with fewer ocular side effects.
As I noted in my editorial, safety remains a 
“potentially profound” issue and “continued vigi-
lance will be important.” Concerns about minute 
circulating levels of bevacizumab and potential 
exacerbation of periventricular leukomalacia and 
bronchopulmonary dysplasia are warranted. How-
ever, the comparison by Gole and colleagues 
between multiple, systemic doses of interferon 
and a single intravitreal dose of bevacizumab 
that is about 0.25% of the normal systemic adult 
dose is problematic.
No study is definitive and no protocol is flaw-
less. The CRYO-ROP investigators selected thresh-
old retinopathy of prematurity as the interven-
tion point, which became the standard of care 
until the ETROP study showed that it is better to 
treat the disease at an earlier point in the disease 
spectrum. Although the issue of adverse events 
is potentially profound, there is little direct sup-
porting evidence of systemic adverse events con-
sequent to the intravitreal injection of bevacizu-
mab. Much more data will be forthcoming, and, 
as stated in my editorial, “as our experience with 
bevacizumab grows, its indications and relative 
contraindications will be refined.” The limited 
use of bevacizumab for zone I retinopathy of 
prematurity must include informed consent that 
is based on a discussion of the known and un-
known risks versus the risk of blindness.
James D. Reynolds, M.D.
University at Buffalo 
Buffalo, NY
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Apixaban in Patients with Atrial Fibrillation
To the Editor: Connolly et al. (March 3 issue) 
report the results of the AVERROES (Apixaban 
Versus Acetylsalicylic Acid [ASA] to Prevent Stroke 
in Atrial Fibrillation Patients Who Have Failed or 
Are Unsuitable for Vitamin K Antagonist Treat-
ment) trial regarding apixaban in patients with 
atrial fibrillation.1 Aspirin has been shown to be 
modestly effective in the primary prevention of 
ischemic strokes in patients with nonvalvular 
atrial fibrillation. Historically, a meta-analysis of 
six major trials comparing aspirin with warfarin 
showed that warfarin significantly reduced the 
rate of ischemic stroke, as compared with aspirin 
(2.0 vs. 4.3 events per 100 patient-years; hazard 
ratio, 0.48).2 It is not surprising that Connolly et 
al. were able to report a benefit with apixaban 
relative to aspirin in reducing the risk of ische-
mic stroke and systemic embolism. These inves-
tigators allowed physicians to choose the dose of 
aspirin administered to the participants. It is also 
important to note that no information was pro-
vided about other medications being taken by the 
participants that might limit aspirin’s effect (e.g., 
nonsteroidal antiinflammatory drugs [NSAIDs]) 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 13, 2014. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
